Payload-linker suite opens

Piramal Pharma Solutions (PPS) has officially unveiled the new payload-linker suite at Riverview, Michigan. The company called this a key element of the broader $90 million investment plan it announced last year to extend US-based manufacturing capabilities, alongside commercial-scale manufacturing at the sterile injectables facility in Lexington, Kentucky.

The Riverside drug substance facility, which was part of Ash Stevens for most of its 60 years, has vast experience in HPAPIs. On the basis of this, it also acts as PPS’s dedicated payload-linker supplier, making it critical to the ADCelerate approach to Phase I ADC development.